Safety and Efficacy of Sitagliptin compared with Glimepiride in Patients with Type 2 Diabetes Mellitus inadequately controlled with Metfromin Monotherapy

Abstract

Background: Type 2 diabetes mellitus (DM) is a life-long disease requiring chronic treatment and management. Therefore, assessment of the long-term safety and tolerability of newer therapeutic agents is of importance. Objective: To compare safety and efficacy of sitagliptin with glimepiride in patients with type 2 diabetes mellitus not adequately controlled with metformin monotherapy. Method: This study was conducted at Pharmacology Department, Gomal Medical College, Dera Ismail Khan from 1st June 2010 to 31st December 2012. Patients of type 2 DM not adequately controlled with a stable dose of metformin (≥ 1500 mg/day) monotherapy were randomized into 02 groups. One group was given sitagliptin 100mg while other group was given glimepiride 2mg once daily for 12 weeks. Primary end point of the study was number of patients achieving the target HbA1C

Keywords

• diabetes mellitus
• sitagliptin
• glimepiride
• hba1c